Global Expansion Sanaria’s PfSPZ-LARC2 trials are being launched in the US and Germany with plans for a global rollout within three years, signaling strong demand for international clinical trial supply, regulatory coordination, and vaccine distribution partnerships.

Cold Chain Leadership Winning the Best Logistics Technology and Cold Chain Delivery Award highlights Sanaria’s strengths in temperature-controlled logistics, creating partnership opportunities with cold chain providers, packaging specialists, and CROs to support large-scale vaccine deployment and storage of challenge materials.

In Vitro Manufacturing Advances in producing PfSPZ in vitro open a path to scalable manufacturing without vectors, enabling potential contracts with manufacturers, technology transfer opportunities, and capacity planning to meet anticipated global demand for malaria vaccines.

Strategic Funding Past funding from the Gates Foundation and EU Malaria Fund demonstrates donor-backed collaboration potential; explore co-development deals, pilot programs with governments or NGOs, and grant-funded initiatives to expand access in Africa and other high-burden regions.

Growth Readiness With revenue in the tens of millions and a small, focused team, Sanaria can partner with larger pharma, contract research organizations, and research networks to scale manufacturing, distribution, and clinical trial services, leveraging existing tech platforms for stakeholder engagement.